Emily Malm
Nurse Practitioner · Whittier, CANPI 1801128681
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.6% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2022 at $10,802 and has fallen 99.5% since, to $50 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $54.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Teva Pharmaceuticals USA, Inc.$927
- Lundbeck LLC$811
- Livanova USA, Inc.$782
- AstraZeneca$640
- SK Life Science, Inc.$634
- plus $7K from 45 others
What the payments were for
- Speaking & faculty fees$18,51357%
- Travel & lodging$7942%
- Food & beverage$13,11140%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,477 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 23 | $56,406 |
| RytaryCarbidopa/Levodopa | 21 | $44,271 |
| AptiomEslicarbazepine Acetate | 13 | $34,523 |
| BriviactBrivaracetam | 22 | $32,504 |
| UbrelvyUbrogepant | 15 | $22,676 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $18,487 |
| FycompaPerampanel | 12 | $15,071 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $10,251 |
| Sumatriptan Succinate | 22 | $3,242 |
| Diclofenac Potassium | 11 | $2,942 |
| Levetiracetam | 57 | $2,677 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 69 | $2,498 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $2,335 |
| Memantine Hcl | 21 | $1,853 |
| Memantine Hcl ErMemantine Hcl | 18 | $1,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $568 | $56,40623 claims |
| Amneal Pharmaceuticals LLCRytary | $284 | $44,27121 claims |
| AbbVieUbrelvy, Namzaric | $21,614 | $32,92632 claims |
| UCB, Inc.Briviact | $520 | $32,50422 claims |
| Eisai Inc.Fycompa | $366 | $15,07112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Whittier
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.